Can GSK’s Blenrep Make A Comeback After Beating Darzalex? Eye Toxicity Concerns Remain
GSK will talk to regulators about bringing Blenrep back in earlier-stage myeloma patients, likely arguing that its convenience is greater than for CAR-T and carries a lower infection risk than bispecifics.
You may also be interested in...
The company’s PD-1 inhibitor Jemperli plus GSK's own PARP Zejula has scored a win in a late-stage endometrial cancer trial that could lead to a key label expansion.
In this week's podcast edition of Five Must-Know Things: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.
The DREAMM-3 study was meant to be a confirmatory study for Blenrep, and its failure raises concerns over its use in earlier lines of therapy and the possibility that it could be removed from the market.